Published in J Gastroenterol on February 16, 2007
Crohn's disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med (2009) 1.71
A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am J Pathol (2009) 1.70
Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol (2010) 1.58
Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol (2008) 1.48
Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. J Gastroenterol (2012) 1.40
Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol (2011) 1.35
Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease. J Gastroenterol (2012) 1.31
Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci (2011) 1.30
IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am J Pathol (2011) 1.29
Crohn disease: a current perspective on genetics, autophagy and immunity. Autophagy (2011) 1.26
Inflammation and gastrointestinal Candida colonization. Curr Opin Microbiol (2011) 1.25
Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol (2011) 1.23
Colitis and cancer: a tale of inflammatory cells and their cytokines. J Clin Invest (2008) 1.21
Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol (2008) 1.19
The role of chemokines in intestinal inflammation and cancer. Curr Opin Pharmacol (2009) 1.16
Inflammatory bowel disease: Moving toward a stem cell-based therapy. World J Gastroenterol (2008) 1.10
Gastroduodenitis associated with ulcerative colitis. J Gastroenterol (2008) 1.05
The Role of Inflammation in the Pathogenesis of Colorectal Cancer. Curr Colorectal Cancer Rep (2009) 1.04
Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis (2015) 1.00
Immunosuppressive exosomes from TGF-β1 gene-modified dendritic cells attenuate Th17-mediated inflammatory autoimmune disease by inducing regulatory T cells. Cell Res (2011) 0.98
Involvement of MAPK/NF-κB signaling in the activation of the cholinergic anti-inflammatory pathway in experimental colitis by chronic vagus nerve stimulation. PLoS One (2013) 0.98
Dextran sulfate sodium and 2,4,6-trinitrobenzene sulfonic acid induce lipid peroxidation by the proliferation of intestinal gram-negative bacteria in mice. J Inflamm (Lond) (2010) 0.93
Use of small bowel imaging for the diagnosis and staging of Crohn's disease--a survey of current UK practice. Br J Radiol (2010) 0.93
The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease. Clin Exp Immunol (2010) 0.92
Endoplasmic reticulum stress in hepatic steatosis and inflammatory bowel diseases. Front Genet (2014) 0.91
Bovine glycomacropeptide ameliorates experimental rat ileitis by mechanisms involving downregulation of interleukin 17. Br J Pharmacol (2008) 0.91
Disturbances in metabolic, transport and structural genes in experimental colonic inflammation in the rat: a longitudinal genomic analysis. BMC Genomics (2008) 0.88
Stem cells as potential therapeutic targets for inflammatory bowel disease. Front Biosci (Schol Ed) (2010) 0.87
Infection with Hymenolepis diminuta is more effective than daily corticosteroids in blocking chemically induced colitis in mice. J Biomed Biotechnol (2010) 0.87
The neurotensin-HIF-1α-VEGFα axis orchestrates hypoxia, colonic inflammation, and intestinal angiogenesis. Am J Pathol (2014) 0.85
Virulence factors of Enterococcus strains isolated from patients with inflammatory bowel disease. World J Gastroenterol (2013) 0.84
An angiotensin II receptor antagonist reduces inflammatory parameters in two models of colitis. Regul Pept (2007) 0.84
Decreased production of interleukin-10 and transforming growth factor-β in Toll-like receptor-activated intestinal B cells in SAMP1/Yit mice. Immunology (2010) 0.83
Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus. ISRN Gastroenterol (2013) 0.83
Maternal country of origin, breast milk characteristics and potential influences on immunity in offspring. Clin Exp Immunol (2010) 0.82
Cellobiose Prevents the Development of Dextran Sulfate Sodium (DSS)-Induced Experimental Colitis. J Clin Biochem Nutr (2010) 0.82
Markers of Inflammation and Lineage on Exfoliated Colonic Cells In Pediatric Inflammatory Bowel Disease. J Gastrointest Dig Syst (2011) 0.82
BTZO-15, an ARE-activator, ameliorates DSS- and TNBS-induced colitis in rats. PLoS One (2011) 0.81
Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease. World J Gastroenterol (2014) 0.81
Lemon verbena infusion consumption attenuates oxidative stress in dextran sulfate sodium-induced colitis in the rat. Dig Dis Sci (2011) 0.81
Proteasome inhibitor bortezomib ameliorates intestinal injury in mice. PLoS One (2012) 0.81
Costimulation of Th17 cells: Adding fuel or putting out the fire in the inflamed gut? Semin Immunopathol (2010) 0.80
Association of STAT4 gene rs7574865G > T polymorphism with ulcerative colitis risk: evidence from 1532 cases and 3786 controls. Arch Med Sci (2014) 0.79
Glucocorticoids differentially regulate Na-bile acid cotransport in normal and chronically inflamed rabbit ileal villus cells. Am J Physiol Gastrointest Liver Physiol (2010) 0.79
Enterococcus durans TN-3 Induces Regulatory T Cells and Suppresses the Development of Dextran Sulfate Sodium (DSS)-Induced Experimental Colitis. PLoS One (2016) 0.79
FR167653, a p38 mitogen-activated protein kinase inhibitor, aggravates experimental colitis in mice. World J Gastroenterol (2008) 0.79
Induction of experimental acute ulcerative colitis in rats by administration of dextran sulfate sodium at low concentration followed by intracolonic administration of 30% ethanol. J Zhejiang Univ Sci B (2007) 0.78
Molecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseases. Antioxid Redox Signal (2013) 0.78
Nutritional therapy for active Crohn's disease. World J Gastroenterol (2008) 0.78
Temporal and spatial dependence of inflammatory biomarkers and suppression by fluvastatin in dextran sodium sulfate-induced rat colitis model. Dig Dis Sci (2014) 0.78
Anti-inflammatory efficiency of levobupivacaine in an experimental colitis model. World J Gastroenterol (2010) 0.78
The Sasa quelpaertensis Leaf Extract Inhibits the Dextran Sulfate Sodium-induced Mouse Colitis Through Modulation of Antioxidant Enzyme Expression. J Cancer Prev (2015) 0.77
Heterozygous nucleotide-binding oligomerization domain-2 mutations affect monocyte maturation in Crohn's disease. World J Gastroenterol (2007) 0.76
Can nicotine use alleviate symptoms of psoriasis? Can Fam Physician (2012) 0.76
Takayasu's arteritis associated with Crohn's disease. J Zhejiang Univ Sci B (2009) 0.75
Ratio of Circulating Estrogen Receptors Beta and Alpha (ERβ/ERα) Indicates Endoscopic Activity in Patients with Crohn's Disease. Dig Dis Sci (2017) 0.75
Fructooligosaccharides exert intestinal anti-inflammatory activity in the CD4+ CD62L+ T cell transfer model of colitis in C57BL/6J mice. Eur J Nutr (2015) 0.75
Impact of basal diet on dextran sodium sulphate (DSS)-induced colitis in rats. Eur J Nutr (2014) 0.75
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
Adhesion receptors of the immune system. Nature (1990) 28.86
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 28.24
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science (2006) 27.49
Inflammatory bowel disease. N Engl J Med (2002) 21.17
Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J (1955) 19.22
A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (1997) 16.28
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Crohn's disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis. Gut (1960) 12.55
The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today (1996) 12.12
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med (1997) 10.67
Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem (2003) 9.37
CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science (2005) 8.97
Lymphocyte responses and cytokines. Cell (1994) 8.35
Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med (2004) 7.93
An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet (1977) 7.89
Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet (2001) 7.27
Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell (1993) 7.10
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Natalizumab for active Crohn's disease. N Engl J Med (2003) 6.44
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med (2005) 6.37
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 6.33
Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med (1994) 6.05
NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol (2004) 5.59
Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest (2004) 5.39
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 5.34
Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science (2005) 5.25
Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet (1991) 5.02
Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med (1995) 4.56
Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology (2004) 4.42
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology (2003) 4.40
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 4.39
Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology (2005) 4.10
Non-smoking: a feature of ulcerative colitis. Br Med J (Clin Res Ed) (1982) 4.08
Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet (1974) 4.06
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med (2005) 3.56
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology (1995) 3.44
Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med (2002) 3.31
Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev (2001) 3.31
Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology (1987) 3.24
Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology (2002) 3.21
Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med (1980) 3.01
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med (2000) 2.78
Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet (2002) 2.74
Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol (2004) 2.53
Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol (1996) 2.42
The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther (1972) 2.37
Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut (1993) 2.35
Appendectomy and subsequent risk of inflammatory bowel diseases. Surgery (2001) 2.35
Sargramostim for active Crohn's disease. N Engl J Med (2005) 2.24
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 2.21
Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut (1994) 2.06
Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut (2003) 2.02
Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet (1993) 2.00
Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. J Exp Med (2005) 1.90
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut (2005) 1.84
CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon gamma production. J Exp Med (1994) 1.76
Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2005) 1.73
Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology (2001) 1.73
Straight ileoanal anastomosis v ileal pouch--anal anastomosis after colectomy and mucosal proctectomy. Arch Surg (1983) 1.63
Time relationships between cessation of smoking and onset of ulcerative colitis. Digestion (1987) 1.60
Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis (2004) 1.36
Crohn's disease caused by Mycobacterium avium subspecies paratuberculosis: a public health tragedy whose resolution is long overdue. J Med Microbiol (2002) 1.35
Generation of regulatory gut-homing human T lymphocytes using ex vivo interleukin 10 gene transfer. Gastroenterology (2002) 1.35
Effect of resection margins on the recurrence of Crohn's disease in the small bowel. A randomized controlled trial. Ann Surg (1996) 1.30
Review article: the genetics of inflammatory bowel disease. Aliment Pharmacol Ther (2001) 1.25
Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflamm Bowel Dis (2005) 1.23
Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis (2004) 1.22
Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Trends Immunol (2003) 1.22
Are 100,000 "SNPs" useless? Science (2002) 1.20
Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol (1988) 1.18
Regional ileitis: a pathologic and clinical entity. 1932. Mt Sinai J Med (2000) 1.18
Gastrointestinal dendritic cells play a role in immunity, tolerance, and disease. Gastroenterology (2004) 1.17
An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment Pharmacol Ther (2005) 1.11
Historical origins of current IBD concepts. World J Gastroenterol (2001) 1.10
Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database Syst Rev (2004) 1.08
A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis. Gastroenterology (1975) 1.07
Microbial pattern recognition receptors mediate M-cell uptake of a gram-negative bacterium. Infect Immun (2006) 1.05
Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Dig Dis Sci (1985) 1.05
Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease. Dig Dis Sci (2000) 1.05
Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther (2003) 1.03
Probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol (2006) 0.96
Effects of current cigarette smoking on clinical course of Crohn's disease and ulcerative colitis. Dig Dis Sci (2001) 0.96
Experimental models of inflammatory bowel disease. Arch Immunol Ther Exp (Warsz) (2003) 0.91
Update in medical therapy of ulcerative colitis: newer concepts and therapies. J Clin Gastroenterol (2005) 0.91
Lipopolysaccharide-induced human enterocyte tolerance to cytokine-mediated interleukin-8 production may occur independently of TLR-4/MD-2 signaling. Pediatr Res (2005) 0.86
The role of antibiotics in the management of Crohn's disease. Inflamm Bowel Dis (2004) 0.84
Stapler stricturoplasty for Crohn's disease. Surg Gynecol Obstet (1989) 0.78